DNA2.0 Acquires MIGS to Add Antibody Production Capabilities
Integrated Platform Will Accelerate Protein Pharmaceutical Research
DNA2.0 Inc. announced that it has entered into a definitive asset purchase agreement to acquire substantially all of the assets of MIGS LLC. MIGS is a Lebanon, NH-based integrated contract research organization specializing in humanization and the production of antibody and antibody-like molecules that support preclinical studies with microgram to gram quantities of protein. MIGS Founder Dr. Michael Feldhaus will join the DNA2.0 team as senior vice president of antibody technologies.
"We are delighted to welcome the MIGS team into DNA2.0," said Jeremy Minshull, PhD, CEO of DNA2.0. "MIGS' antibody expertise and protein expression technology is a great fit with DNA2.0's industrialized bioengineering pipeline. We aim to provide an unparalleled antibody production and engineering platform under one roof, and together we will continue to provide the excellent customer service MIGS customers expect, while growing our service offerings."
DNA2.0 has recently expanded into a new 50,000 SF facility in Newark, CA, allowing the company to make a significant investment in mammalian protein production capacity. "With MIGS' antibody expertise, we now have the ability to go from virtual sequence to producing proteins at gram-scale in mammalian cells," said Dr. Minshull. "Adding this to our machine learning and DNA synthesis platforms, we aim to help our customers to reimagine their research."
"We are excited to join forces with DNA2.0," said Michael Feldhaus, PhD, founder and CEO of MIGS. "We have worked closely with DNA2.0 for some time and there is a clear opportunity for us to be more than the sum of our parts. MIGS customers will continue to have access to the highly integrated synthesis through purification process that delivers highly characterized antibody and antibody-like molecules in only a couple of weeks' time. Customers will now also have access to DNA2.0's next generation of mammalian expression vectors, translating into higher yields and faster turnaround times. We believe the protein pharmaceutical market will find this integrated offering an exceptional platform to accelerate their research."
MIGS CEO Michael Feldhaus and key personnel will transfer to the DNA2.0 site in Newark, CA. Terms of the deal were not disclosed.
DNA2.0 is the leading bioengineering solutions provider, offering an integrated pipeline of solutions including gene design, optimization and synthesis, expression vectors, and platforms for protein and strain engineering. DNA2.0 explores novel applications for synthetic genes and the synergy between efficient gene design and protein optimization technologies. DNA2.0's tools and solutions are fueling the transformation of biology from a discovery science to an engineering discipline. The company is privately held and is headquartered in Newark, California. For more information, please visit http://www.DNA20.com.
MIGS was founded by two world renowned antibody engineers, Michael Feldhaus and James Marks, who have a combined total of greater than 150 papers in the field, greater than 100 patents in the antibody space, and more than 15 antibodies currently in clinical trials or approved for clinical use. The founders' vast experience was leveraged to build the company's unparalleled antibody production and analysis platform, which is applied to humanization and antibody engineering projects.